Literature DB >> 15622318

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Patrick M Tarwater1, Joel E Gallant, John W Mellors, Mary E Gore, John P Phair, Roger Detels, Joseph B Margolick, Alvaro Muñoz.   

Abstract

BACKGROUND: The study objective was to compare the prognostic value of plasma HIV RNA and CD4 cell count at baseline and as time-updated variables in highly active antiretroviral therapy (HAART) users for two outcomes: development of AIDS and change in CD4 cell count.
METHODS: The study population comprised 387 men enrolled in the Multicenter AIDS Cohort Study who were AIDS-free and initiated HAART between 1996 and 2001. Follow-up until AIDS diagnosis (n=36, 9%) or the last AIDS-free visit was included. To determine the predictive value of combining HIV RNA and CD4 cell count, regression tree methods using recursive partitioning at pre-specified cut points for both variables were used.
RESULTS: Low CD4 cell count was a strong predictor of AIDS among HAART users. However, HIV RNA showed strong prognostic value for AIDS development among those with CD4 cell counts > 250 x 10(6) cells/l, in whom an HIV RNA level > 1000 copies/ml carried a 4.6-fold greater risk of developing AIDS. HIV RNA < 5000 copies/ml was also predictive of subsequent increase in CD4 cell count with significantly higher increases among those with initial CD4 counts > 300 x 10(6) cells/l.
CONCLUSION: Although, in HAART users, CD4 cell count was the primordial prognostic marker, an HIV RNA > 1000 copies/ml attained after HAART initiation was a strong predictor of the rate of subsequent CD4 cell count increase and of developing AIDS in patients whose CD4 cell counts were > 250 x 10(6) cells/l.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15622318

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

1.  Short-term clinical outcomes among treatment-experienced HIV-positive patients with early low level viremia.

Authors:  Chun Chao; Beth Tang; William Towner; Michael J Silverberg; Leo Hurley; Michael Horberg
Journal:  AIDS Patient Care STDS       Date:  2012-03-16       Impact factor: 5.078

2.  Change over time of mortality predictors after HAART initiation in a Senegalese cohort.

Authors:  Pierre De Beaudrap; Jean-François Etard; René Ecochard; Assane Diouf; Allé Baba Dieng; Vannina Cilote; Ibrahima Ndiaye; Ndèye Fatou Ngom Guèye; Pape Mandoumbé Guèye; Papa Salif Sow; Souleymane Mboup; Ibra Ndoye; Eric Delaporte
Journal:  Eur J Epidemiol       Date:  2008-01-16       Impact factor: 8.082

3.  CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Authors:  Xiuhong Li; Joseph B Margolick; Beth D Jamieson; Charles R Rinaldo; John P Phair; Lisa P Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

4.  Single-copy quantification of HIV-1 in clinical samples.

Authors:  Ann Wiegand; Frank Maldarelli
Journal:  Methods Mol Biol       Date:  2014

5.  Measuring quality of life in rural Uganda: reliability and validity of summary scores from the medical outcomes study HIV health survey (MOS-HIV).

Authors:  Anne L Stangl; Rebecca Bunnell; Nafuna Wamai; Humphrey Masaba; Jonathan Mermin
Journal:  Qual Life Res       Date:  2011-12-25       Impact factor: 4.147

6.  Impaired Neurocognitive Performance and Mortality in HIV: Assessing the Prognostic Value of the HIV-Dementia Scale.

Authors:  Nikhil Banerjee; Roger C McIntosh; Gail Ironson
Journal:  AIDS Behav       Date:  2019-12

7.  Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.

Authors:  Xiuhong Li; Haitao Chu; Joel E Gallant; Donald R Hoover; Wendy J Mack; Joan S Chmiel; Alvaro Muñoz
Journal:  J Epidemiol Community Health       Date:  2006-09       Impact factor: 3.710

8.  Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.

Authors:  Hemant Kulkarni; Jason F Okulicz; Greg Grandits; Nancy F Crum-Cianflone; Michael L Landrum; Braden Hale; Glenn Wortmann; Edmund Tramont; Michael Polis; Matthew Dolan; Alan R Lifson; Brian K Agan; Sunil K Ahuja; Vincent C Marconi
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

9.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

10.  Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand.

Authors:  Trinh Duong; Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sophie Le Cœur; Pacharee Kantipong; Sudanee Buranabanjasatean; Prattana Leenasirimakul; Sriprapar Ariyadej; Somboon Tansuphasawasdikul; Suchart Thongpaen; Marc Lallemant
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.